These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20302403)

  • 1. Pathogenesis of primary acquired nasolacrimal duct obstruction.
    Kashkouli MB; Sadeghipour A; Kaghazkanani R; Bayat A; Pakdel F; Aghai GH
    Orbit; 2010 Feb; 29(1):11-5. PubMed ID: 20302403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective controlled study of vapor pressure tear osmolality and tear meniscus height in nasolacrimal duct obstruction.
    Stahl U; Francis IC; Stapleton F
    Am J Ophthalmol; 2006 Jun; 141(6):1051-6. PubMed ID: 16765672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Videoreflective dacryomeniscometry in normal adults and in patients with functional or primary acquired nasolacrimal duct obstruction.
    Francis IC; Chan DG; Papalkar D; Papas EB; Stapleton F
    Am J Ophthalmol; 2005 Mar; 139(3):493-7. PubMed ID: 15767059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of dye disappearance test and tear meniscus height in diagnosis and postoperative assessment of nasolacrimal duct obstruction.
    Roh JH; Chi MJ
    Acta Ophthalmol; 2010 May; 88(3):e73-7. PubMed ID: 20546233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical glaucoma therapy as a risk factor for nasolacrimal duct obstruction.
    Seider N; Miller B; Beiran I
    Am J Ophthalmol; 2008 Jan; 145(1):120-123. PubMed ID: 17915187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasolacrimal duct obstruction: clinicopathologic analysis of 205 cases.
    Altan-Yaycioglu R; Canan H; Sizmaz S; Bal N; Pelit A; Akova YA
    Orbit; 2010 Oct; 29(5):254-8. PubMed ID: 20704489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Micro-Reflux Test: a new test to evaluate nasolacrimal duct obstruction.
    Camara JG; Santiago MD; Rodriguez RE; Medalle RA; Young DA; Atebara NH
    Ophthalmology; 1999 Dec; 106(12):2319-21. PubMed ID: 10599664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonlaser endoscopic endonasal dacryocystorhinostomy with adjunctive mitomycin C in nasolacrimal duct obstruction in adults.
    Dolmetsch AM
    Ophthalmology; 2010 May; 117(5):1037-40. PubMed ID: 20079535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endoscopic radiofrequency-assisted dacryocystorhinostomy with double stent: a personal experience.
    Javate R; Pamintuan F
    Orbit; 2005 Mar; 24(1):15-22. PubMed ID: 15764111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic dacryocystorhinostomy for acquired nasolacrimal duct obstruction.
    Agarwal S
    J Laryngol Otol; 2009 Nov; 123(11):1226-8. PubMed ID: 19674493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic analysis of 166 patients with primary acquired nasolacrimal duct obstruction.
    Lee-Wing MW; Ashenhurst ME
    Ophthalmology; 2001 Nov; 108(11):2038-40. PubMed ID: 11713075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological study of lacrimal sac specimens obtained during DCR.
    Salour H; Hatami MM; Parvin M; Ferdowsi AA; Abrishami M; Bagheri A; Aletaha M; Yazdani S
    Orbit; 2010 Oct; 29(5):250-3. PubMed ID: 20812824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External versus endoscopic dacryocystorhinostomy for acquired nasolacrimal duct obstruction in a tertiary referral center.
    Ben Simon GJ; Joseph J; Lee S; Schwarcz RM; McCann JD; Goldberg RA
    Ophthalmology; 2005 Aug; 112(8):1463-8. PubMed ID: 15953636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Endoscopic Dacryocystorhinostomy in Secondary Acquired Nasolacrimal Duct Obstruction: A Case-Control Study.
    Sweeney AR; Davis GE; Chang SH; Amadi AJ
    Ophthalmic Plast Reconstr Surg; 2018; 34(1):20-25. PubMed ID: 27997463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic study of lacrimal sac and nasal mucosa in 44 patients with complete acquired nasolacrimal duct obstruction.
    Mauriello JA; Palydowycz S; DeLuca J
    Ophthalmic Plast Reconstr Surg; 1992; 8(1):13-21. PubMed ID: 1554647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etiopathogenesis of primary acquired nasolacrimal duct obstruction (PANDO).
    Ali MJ
    Prog Retin Eye Res; 2023 Sep; 96():101193. PubMed ID: 37394093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrolytes and electrophoretic studies of tear proteins in tears of patients with nasolacrimal duct obstruction.
    Lew H; Yun YS; Lee SY
    Ophthalmologica; 2005; 219(3):142-6. PubMed ID: 15947499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is gastroesophageal reflux disease associated with primary acquired nasolacrimal duct obstruction?
    Mehta S; Ying GS; Hussain A; Harvey JT
    Orbit; 2018 Apr; 37(2):135-139. PubMed ID: 29040001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically suspected primary acquired nasolacrimal duct obstruction: clinicopathologic review of 150 patients.
    Tucker N; Chow D; Stockl F; Codère F; Burnier M
    Ophthalmology; 1997 Nov; 104(11):1882-6. PubMed ID: 9373121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lacrimal Gland Volume Changes in Unilateral Primary Acquired Nasolacrimal Obstruction.
    Yazici A; Bulbul E; Yazici H; Sari E; Tiskaoglu N; Yanik B; Ermis S
    Invest Ophthalmol Vis Sci; 2015 Jul; 56(8):4425-9. PubMed ID: 26193918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.